痰中中性粒细胞肽水平与症状性吸烟者和 COPD 患者。

Human neutrophil peptides sputum levels in symptomatic smokers and COPD patients.

机构信息

Department of Cardiovascular and Respiratory Sciences, Sapienza University of Rome, S. Camillo-Forlanini Hospital, Rome, Italy.

出版信息

Eur Rev Med Pharmacol Sci. 2011 May;15(5):556-62.

PMID:21744752

Abstract

BACKGROUND AND OBJECTIVES

Human Neutrophil Peptides (HNP) are major neutrophils' products which may contribute to the airway inflammation and lung remodelling during chronic obstructive pulmonary disease (COPD). We aimed to assess whether HNP sputum concentrations could be used as indicators of airway inflammation and progression towards pulmonary functional impairment, and correlate with the degree of airways obstruction.

MATERIALS AND METHODS

We measured, by ELISA tests, HNP concentrations from 37 symptomatic smokers and 34 COPD patients. All participants underwent pulmonary function tests. Sputum samples were collected at the enrolment, and 6 months after smoking cessation. Differences between groups and correlation coefficients between variables were determined using non parametric tests.

RESULTS

Sputum HNP concentrations were higher in COPD patients as compared to symptomatic smokers (14 +/- 1.5 microg/ml vs 1.6 +/- 0.4 microg/ml; p < 0.0001). Among COPD patients HNP concentrations were higher in individuals with severe obstruction than in patients with mild to moderate COPD (19.9 +/- 2.3 microg/ml vs 10.3 +/- 0.8 microg/ml, p = 0.003). A negative correlation was observed between HNP levels and FEV1 (rho = -0.38, p = 0.02), and FEV1/FVC (rho = -0.42, p = 0.01). No differences were found in HNP levels before and after 6 months of smoking withdrawal (1.1 microg/ml +/- 0.3 vs 1.1 microg/ml +/- 0.3 for symptomatic smokers, p = 0.9, and 14.4 microg/ml +/- 1 vs 16 microg/ml +/- 1.1 for COPD, p = 0.6).

DISCUSSION

Sputum levels of HNP may represent a marker of severity of functional impairment in COPD. Our data support the hypothesis that HNP may have a role in smoking- and COPD-related lung inflammation.

摘要

背景与目的

人中性粒细胞肽（HNP）是中性粒细胞的主要产物，可能导致慢性阻塞性肺疾病（COPD）期间的气道炎症和肺重塑。我们旨在评估HNP 痰浓度是否可用作气道炎症和向肺功能损害进展的指标，并与气道阻塞程度相关。

材料与方法

我们通过 ELISA 试验测量了 37 名有症状的吸烟者和 34 名 COPD 患者的 HNP 浓度。所有参与者均接受了肺功能测试。在招募时和戒烟 6 个月后采集了痰样。使用非参数检验确定组间差异和变量之间的相关系数。

结果

与有症状的吸烟者相比，COPD 患者的痰 HNP 浓度更高（14 ± 1.5 µg/ml 与 1.6 ± 0.4 µg/ml；p <0.0001）。在 COPD 患者中，严重阻塞患者的 HNP 浓度高于轻度至中度 COPD 患者（19.9 ± 2.3 µg/ml 与 10.3 ± 0.8 µg/ml，p = 0.003）。HNP 水平与 FEV1（rho = -0.38，p = 0.02）和 FEV1/FVC（rho = -0.42，p = 0.01）呈负相关。戒烟 6 个月前后 HNP 水平无差异（有症状的吸烟者为 1.1 µg/ml ± 0.3 与 1.1 µg/ml ± 0.3，p = 0.9，COPD 患者为 14.4 µg/ml ± 1 与 16 µg/ml ± 1.1，p = 0.6）。